Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing Hospital

About this trial

The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)

50×10^9/L>PLT

anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center

Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)

Disqualifiers

Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening

Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)

Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on

Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Telitacicept

    Biological/Vaccine

    subcutaneous telitacicept 160 mg weekly for 24 weeks.

  • Placebo

    Drug

    subcutaneous placebo weekly for 24 weeks.

Treatment groups

296 Participants
are divided into 2 treatment groups
Group A: Telitacicept plus standard therapyExperimental treatment 1 intervention
Group B: Placebo plus standard therapyPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Overall response (CR + PR) rate

Response is deemed as complete (CR) if the platelet (PLT) count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.

Time frame
at week 24

Secondary outcomes

1

Overall response (CR + PR) rate

Response is deemed as complete (CR) if the platelet count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.

Time frame
at week 12
2

Rescue treatment rate

Rescue treatment is initiated if the platelet count is \<10×10\^9/L, or the participant is with active bleeding, or based on the investigator's judgement when the platelet count ranges from 10×10\^9/L to 30×10\^9/L.

Time frame
at week 24
3

Time to rescue treatment

Time to rescue treatment refers to period duration from the initiation of Telitacicept or placebo (day 1) to rescue treatment.

Time frame
at week 24
4

Relapse rate

No response refers to the platelet count is \< 50×10\^9/L, or increases for less than 1-fold from baseline, or with active central nervous system or digestive tract bleeding, or rescue treatment is initiated. Relapse is defined as no response recurring after a complete or partial response lasting for at least 7 days with treatment.

Time frame
at week 24

Other outcomes

1

life quality 1

According to the ITP Patient Assessment Questionnaire™ (ITP-PAQ™) score. The ITP-PAQ™ is a disease-specific instrument that was designed to measure the Quality of Life (QoL) of adult patients with immune thrombocytopenia. The items employ a 4-week recall with responses recorded on 4-, 5- or 7-point Likert scales. All item scores are transformed to a 0 to 100 continuum where higher scores represent better QoL and are weighted equally to derive the scale scores.

Time frame
at week 24
2

life quality 2

According to the FACT-Th6 score. The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th6) consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Items were reverse-scored as necessary such that higher scores represent higher Health-related quality of life (HRQoL). Total scores ranged from 0 to 24. Recall period is previous 7 days.

Time frame
at week 24
3

Absolute change rate from baseline in serum immunoglobulin G (IgG)

(serum IgG level at week 24-serum IgG level at baseline)/ serum IgG level at baseline

Time frame
at week 24
4

Absolute change rate from baseline in serum immunoglobulin M (IgM)

(serum IgM level at week 24-serum IgM level at baseline)/ serum IgM level at baseline

Time frame
at week 24

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beijing Hospital

Lead sponsor

The First Affiliated Hospital of Anhui Medical University

Collaborator

The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)

Collaborator

Peking University People's Hospital

Collaborator

Peking University Third Hospital

Collaborator

First Affiliated Hospital, Sun Yat-Sen University

Collaborator

Guangdong Provincial People's Hospital

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator

Second Xiangya Hospital of Central South University

Collaborator

Xiangya Hospital of Central South University

Collaborator

The Affiliated Hospital of Inner Mongolia Medical University

Collaborator

First Hospital of China Medical University

Collaborator

Shandong Provincial Hospital

Collaborator

Changhai Hospital

Collaborator

RenJi Hospital

Collaborator

Shanxi Bethune Hospital

Collaborator

West China Hospital

Collaborator

Institute of Hematology & Blood Diseases Hospital, China

Collaborator

Tianjin First Central Hospital

Collaborator

Tianjin Medical University General Hospital

Collaborator

People's Hospital of Xinjiang Uygur Autonomous Region

Collaborator

The First People's Hospital of Yunnan

Collaborator